https://wiki.cakele.iodatalabs.dev/index.php?action=history&feed=atom&title=DGI%3AAntibiotikatherapie_bei_Sepsis%2FQuellen
DGI:Antibiotikatherapie bei Sepsis/Quellen - Revision history
2026-06-10T23:48:49Z
Revision history for this page on the wiki
MediaWiki 1.41.5
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4193&oldid=prev
imported>Bestem at 18:35, 17 June 2021
2021-06-17T18:35:32Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 18:35, 17 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7">Line 7:</td>
<td colspan="2" class="diff-lineno">Line 7:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10.1007/s00134-018-5085-0]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10.1007/s00134-018-5085-0]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*Leitlinienprogramm DGU: Interdisziplinäre S3 Leitlinie: Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Langversion 1.1-2, 2017 AWMF Registernummer: 043/044, <nowiki>http://www.awmf.org/uploads/tx_szleitlinien/043-</nowiki> 044l_S3_Harnwegsinfektionen pdf (Zugriff am: <del style="font-weight: bold; text-decoration: none;">TT</del>.<del style="font-weight: bold; text-decoration: none;">MM</del>.<del style="font-weight: bold; text-decoration: none;">JJ</del>).</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*Leitlinienprogramm DGU: Interdisziplinäre S3 Leitlinie: Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Langversion 1.1-2, 2017 AWMF Registernummer: 043/044, <nowiki>http://www.awmf.org/uploads/tx_szleitlinien/043-</nowiki> 044l_S3_Harnwegsinfektionen pdf (Zugriff am: <ins style="font-weight: bold; text-decoration: none;">17</ins>.<ins style="font-weight: bold; text-decoration: none;">06</ins>.<ins style="font-weight: bold; text-decoration: none;">21</ins>).</div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4192:rev-4193:php=table -->
</table>
imported>Bestem
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4192&oldid=prev
imported>Bestem at 18:35, 17 June 2021
2021-06-17T18:35:13Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 18:35, 17 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7">Line 7:</td>
<td colspan="2" class="diff-lineno">Line 7:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10.1007/s00134-018-5085-0]</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10.1007/s00134-018-5085-0]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten <del style="font-weight: bold; text-decoration: none;">Aktualisierung </del>2017</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*<ins style="font-weight: bold; text-decoration: none;">Leitlinienprogramm DGU: </ins>Interdisziplinäre S3 Leitlinie<ins style="font-weight: bold; text-decoration: none;">: </ins>Epidemiologie, Diagnostik, Therapie<ins style="font-weight: bold; text-decoration: none;">, </ins>Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten<ins style="font-weight: bold; text-decoration: none;">. Langversion 1.1-2, </ins>2017 <ins style="font-weight: bold; text-decoration: none;">AWMF Registernummer: 043/044, <nowiki>http://www.awmf.org/uploads/tx_szleitlinien/043-</nowiki> 044l_S3_Harnwegsinfektionen pdf (Zugriff am: TT.MM.JJ).</ins></div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4191:rev-4192:php=table -->
</table>
imported>Bestem
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4191&oldid=prev
imported>Bestem at 09:41, 17 June 2021
2021-06-17T09:41:05Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:41, 17 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Interdisziplinäre </del>S3 Leitlinie <del style="font-weight: bold; text-decoration: none;">Epidemiologie</del>, <del style="font-weight: bold; text-decoration: none;">Diagnostik</del>, <del style="font-weight: bold; text-decoration: none;">Therapie Prävention </del>und <del style="font-weight: bold; text-decoration: none;">Management unkomplizierter</del>, <del style="font-weight: bold; text-decoration: none;">bakterieller</del>, <del style="font-weight: bold; text-decoration: none;">ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Dalhoff K, Abele-Horn M, Andreas S, et al. Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017: </ins>S3<ins style="font-weight: bold; text-decoration: none;">-</ins>Leitlinie <ins style="font-weight: bold; text-decoration: none;">der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V., der Deutschen Gesellschaft für Infektiologie e.V.</ins>, <ins style="font-weight: bold; text-decoration: none;">der Deutschen Gesellschaft für Hygiene und Mikrobiologie e.V.</ins>, <ins style="font-weight: bold; text-decoration: none;">der Deutschen Gesellschaft für Pneumologie </ins>und <ins style="font-weight: bold; text-decoration: none;">Beatmungsmedizin e.V.</ins>, <ins style="font-weight: bold; text-decoration: none;">der Paul-Ehrlich Gesellschaft für Chemotherapie e.V</ins>, <ins style="font-weight: bold; text-decoration: none;">der Deutschen Röntgengesellschaft und der Gesellschaft für Virologie. ''Pneumologie''. 2018;72(01):15-63. doi:[https://doi.org/10.1055/s-0043-121734 10.1055/s-0043-121734]</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Dalhoff </del>K<del style="font-weight: bold; text-decoration: none;">, Abele</del>-<del style="font-weight: bold; text-decoration: none;">Horn M, Andreas S, et al</del>. <del style="font-weight: bold; text-decoration: none;">Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie </del>– Update <del style="font-weight: bold; text-decoration: none;">2017</del>: <del style="font-weight: bold; text-decoration: none;">S3</del>-Leitlinie <del style="font-weight: bold; text-decoration: none;">der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V., der Deutschen Gesellschaft für Infektiologie e.V., der Deutschen Gesellschaft für Hygiene und Mikrobiologie e.V., der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V., </del>der Paul-Ehrlich Gesellschaft für Chemotherapie e.V<del style="font-weight: bold; text-decoration: none;">, der Deutschen Röntgengesellschaft und der Gesellschaft für Virologie</del>. ''<del style="font-weight: bold; text-decoration: none;">Pneumologie</del>''. <del style="font-weight: bold; text-decoration: none;">2018</del>;<del style="font-weight: bold; text-decoration: none;">72</del>(<del style="font-weight: bold; text-decoration: none;">01</del>):<del style="font-weight: bold; text-decoration: none;">15</del>-<del style="font-weight: bold; text-decoration: none;">63</del>. doi:[https://doi.org/10.1055/s-0043-<del style="font-weight: bold; text-decoration: none;">121734 </del>10.1055/s-0043-<del style="font-weight: bold; text-decoration: none;">121734</del>]</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Bodmann </ins>K-<ins style="font-weight: bold; text-decoration: none;">F</ins>. <ins style="font-weight: bold; text-decoration: none;">Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen </ins>– Update <ins style="font-weight: bold; text-decoration: none;">2018</ins>: <ins style="font-weight: bold; text-decoration: none;">Intensivmedizinisch relevante Veränderungen in der S2k</ins>-Leitlinie der Paul-Ehrlich<ins style="font-weight: bold; text-decoration: none;">-</ins>Gesellschaft für Chemotherapie e. V. ''<ins style="font-weight: bold; text-decoration: none;">Dtsch med Wochenschr</ins>''. <ins style="font-weight: bold; text-decoration: none;">2019</ins>;<ins style="font-weight: bold; text-decoration: none;">144</ins>(<ins style="font-weight: bold; text-decoration: none;">11</ins>):<ins style="font-weight: bold; text-decoration: none;">729</ins>-<ins style="font-weight: bold; text-decoration: none;">733</ins>. doi:[https://doi.org/10.1055/s-0043-<ins style="font-weight: bold; text-decoration: none;">114874 </ins>10.1055/s-0043-<ins style="font-weight: bold; text-decoration: none;">114874</ins>]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Bodmann K</del>-<del style="font-weight: bold; text-decoration: none;">F. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</del>: <del style="font-weight: bold; text-decoration: none;">Intensivmedizinisch relevante Veränderungen in der S2k-Leitlinie der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V</del>. ''<del style="font-weight: bold; text-decoration: none;">Dtsch med Wochenschr</del>''. <del style="font-weight: bold; text-decoration: none;">2019</del>;<del style="font-weight: bold; text-decoration: none;">144</del>(<del style="font-weight: bold; text-decoration: none;">11</del>):<del style="font-weight: bold; text-decoration: none;">729</del>-<del style="font-weight: bold; text-decoration: none;">733</del>. doi:[https://doi.org/10.<del style="font-weight: bold; text-decoration: none;">1055</del>/<del style="font-weight: bold; text-decoration: none;">s</del>-<del style="font-weight: bold; text-decoration: none;">0043</del>-<del style="font-weight: bold; text-decoration: none;">114874 </del>10.<del style="font-weight: bold; text-decoration: none;">1055</del>/<del style="font-weight: bold; text-decoration: none;">s</del>-<del style="font-weight: bold; text-decoration: none;">0043</del>-<del style="font-weight: bold; text-decoration: none;">114874</del>]</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis</ins>-<ins style="font-weight: bold; text-decoration: none;">prevention, diagnosis, therapy, and aftercare </ins>: <ins style="font-weight: bold; text-decoration: none;">Long version]</ins>. ''<ins style="font-weight: bold; text-decoration: none;">Med Klin Intensivmed Notfmed</ins>''. <ins style="font-weight: bold; text-decoration: none;">2020</ins>;<ins style="font-weight: bold; text-decoration: none;">115</ins>(<ins style="font-weight: bold; text-decoration: none;">Suppl 2</ins>):<ins style="font-weight: bold; text-decoration: none;">37</ins>-<ins style="font-weight: bold; text-decoration: none;">109</ins>. doi:[https://doi.org/10.<ins style="font-weight: bold; text-decoration: none;">1007</ins>/<ins style="font-weight: bold; text-decoration: none;">s00063-020</ins>-<ins style="font-weight: bold; text-decoration: none;">00685</ins>-<ins style="font-weight: bold; text-decoration: none;">0 </ins>10.<ins style="font-weight: bold; text-decoration: none;">1007</ins>/<ins style="font-weight: bold; text-decoration: none;">s00063-020</ins>-<ins style="font-weight: bold; text-decoration: none;">00685</ins>-<ins style="font-weight: bold; text-decoration: none;">0</ins>]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Brunkhorst FM</del>, <del style="font-weight: bold; text-decoration: none;">Weigand MA</del>, <del style="font-weight: bold; text-decoration: none;">Pletz M, et al</del>. <del style="font-weight: bold; text-decoration: none;">[S3 Guideline </del>Sepsis<del style="font-weight: bold; text-decoration: none;">-prevention, diagnosis, therapy, and aftercare </del>: <del style="font-weight: bold; text-decoration: none;">Long version]</del>. ''Med <del style="font-weight: bold; text-decoration: none;">Klin Intensivmed Notfmed</del>''. <del style="font-weight: bold; text-decoration: none;">2020</del>;<del style="font-weight: bold; text-decoration: none;">115</del>(<del style="font-weight: bold; text-decoration: none;">Suppl 2</del>):<del style="font-weight: bold; text-decoration: none;">37</del>-<del style="font-weight: bold; text-decoration: none;">109</del>. doi:[https://doi.org/10.1007/<del style="font-weight: bold; text-decoration: none;">s00063</del>-<del style="font-weight: bold; text-decoration: none;">020</del>-<del style="font-weight: bold; text-decoration: none;">00685</del>-0 10.1007/<del style="font-weight: bold; text-decoration: none;">s00063</del>-<del style="font-weight: bold; text-decoration: none;">020</del>-<del style="font-weight: bold; text-decoration: none;">00685</del>-0]</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Levy MM</ins>, <ins style="font-weight: bold; text-decoration: none;">Evans LE</ins>, <ins style="font-weight: bold; text-decoration: none;">Rhodes A</ins>. <ins style="font-weight: bold; text-decoration: none;">The Surviving </ins>Sepsis <ins style="font-weight: bold; text-decoration: none;">Campaign Bundle</ins>: <ins style="font-weight: bold; text-decoration: none;">2018 update</ins>. ''<ins style="font-weight: bold; text-decoration: none;">Intensive Care </ins>Med''. <ins style="font-weight: bold; text-decoration: none;">2018</ins>;<ins style="font-weight: bold; text-decoration: none;">44</ins>(<ins style="font-weight: bold; text-decoration: none;">6</ins>):<ins style="font-weight: bold; text-decoration: none;">925</ins>-<ins style="font-weight: bold; text-decoration: none;">928</ins>. doi:[https://doi.org/10.1007/<ins style="font-weight: bold; text-decoration: none;">s00134</ins>-<ins style="font-weight: bold; text-decoration: none;">018</ins>-<ins style="font-weight: bold; text-decoration: none;">5085</ins>-0 10.1007/<ins style="font-weight: bold; text-decoration: none;">s00134</ins>-<ins style="font-weight: bold; text-decoration: none;">018</ins>-<ins style="font-weight: bold; text-decoration: none;">5085</ins>-0]</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">Levy MM</del>, <del style="font-weight: bold; text-decoration: none;">Evans LE</del>, <del style="font-weight: bold; text-decoration: none;">Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10.1007/s00134-018-5085-0]</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*Interdisziplinäre S3 Leitlinie Epidemiologie</ins>, <ins style="font-weight: bold; text-decoration: none;">Diagnostik</ins>, <ins style="font-weight: bold; text-decoration: none;">Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</ins></div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4190:rev-4191:php=table -->
</table>
imported>Bestem
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4190&oldid=prev
imported>Bestem at 09:40, 17 June 2021
2021-06-17T09:40:34Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:40, 17 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">*</del>Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):<del style="font-weight: bold; text-decoration: none;">37–109</del>. </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">*<span class="s1"></del>Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 <del style="font-weight: bold; text-decoration: none;"><span class="s2"></del>10.1007/s00134-018-5085-0<del style="font-weight: bold; text-decoration: none;"></span></del>]<del style="font-weight: bold; text-decoration: none;"></span></del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Dalhoff K, Abele-Horn M, Andreas S, et al. Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017: S3-Leitlinie der Deutschen Gesellschaft für Anästhesiologie und Intensivmedizin e.V., der Deutschen Gesellschaft für Infektiologie e.V., der Deutschen Gesellschaft für Hygiene und Mikrobiologie e.V., der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V., der Paul-Ehrlich Gesellschaft für Chemotherapie e.V, der Deutschen Röntgengesellschaft und der Gesellschaft für Virologie. ''Pneumologie''. 2018;72(01):15-63. doi:[https://doi.org/10.1055/s-0043-121734 10.1055/s-0043-121734]</ins></div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Bodmann K-F. Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018: Intensivmedizinisch relevante Veränderungen in der S2k-Leitlinie der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. ''Dtsch med Wochenschr''. 2019;144(11):729-733. doi:[https://doi.org/10.1055/s-0043-114874 10.1055/s-0043-114874]</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. <ins style="font-weight: bold; text-decoration: none;">''</ins>Med Klin Intensivmed Notfmed<ins style="font-weight: bold; text-decoration: none;">''. </ins>2020;115(Suppl 2):<ins style="font-weight: bold; text-decoration: none;">37-109</ins>. <ins style="font-weight: bold; text-decoration: none;">doi:[https://doi.org/10.1007/s00063-020-00685-0 10.1007/s00063-020-00685-0]</ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10.1007/s00134-018-5085-0]</div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4189:rev-4190:php=table -->
</table>
imported>Bestem
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4189&oldid=prev
imported>Maximilian.schons@uk-koeln.de at 04:39, 15 June 2021
2021-06-15T04:39:02Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:39, 15 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):37–109. </div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):37–109. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10.1007/s00134-018-5085-0]</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*<ins style="font-weight: bold; text-decoration: none;"><span class="s1"></ins>Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. ''Intensive Care Med''. 2018;44(6):925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 <ins style="font-weight: bold; text-decoration: none;"><span class="s2"></ins>10.1007/s00134-018-5085-0<ins style="font-weight: bold; text-decoration: none;"></span></ins>]<ins style="font-weight: bold; text-decoration: none;"></span></ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td></tr>
</table>
imported>Maximilian.schons@uk-koeln.de
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4188&oldid=prev
imported>Maximilian.schons@uk-koeln.de at 04:37, 15 June 2021
2021-06-15T04:37:28Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 04:37, 15 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):37–109. </div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):37–109. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med 2018;44(6):<del style="font-weight: bold; text-decoration: none;">925–8</del>. </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. <ins style="font-weight: bold; text-decoration: none;">''</ins>Intensive Care Med<ins style="font-weight: bold; text-decoration: none;">''. </ins>2018;44(6):<ins style="font-weight: bold; text-decoration: none;">925-928. doi:[https://doi.org/10.1007/s00134-018-5085-0 10</ins>.<ins style="font-weight: bold; text-decoration: none;">1007/s00134-018-5085-0]</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4187:rev-4188:php=table -->
</table>
imported>Maximilian.schons@uk-koeln.de
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4187&oldid=prev
imported>Maximilian.schons@uk-koeln.de at 08:23, 14 June 2021
2021-06-14T08:23:07Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 08:23, 14 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):37–109.</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*Brunkhorst FM, Weigand MA, Pletz M, et al. [S3 Guideline Sepsis-prevention, diagnosis, therapy, and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):37–109. </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*The Surviving Sepsis Campaign Bundle: 2018 <del style="font-weight: bold; text-decoration: none;">Update</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*<ins style="font-weight: bold; text-decoration: none;">Levy MM, Evans LE, Rhodes A. </ins>The Surviving Sepsis Campaign Bundle: 2018 <ins style="font-weight: bold; text-decoration: none;">update. Intensive Care Med 2018;44(6):925–8. </ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4186:rev-4187:php=table -->
</table>
imported>Maximilian.schons@uk-koeln.de
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4186&oldid=prev
imported>Maximilian.schons@uk-koeln.de at 08:21, 14 June 2021
2021-06-14T08:21:12Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 08:21, 14 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>*S3-<del style="font-weight: bold; text-decoration: none;">Leitlinie Sepsis – Prävention</del>, <del style="font-weight: bold; text-decoration: none;">Diagnose</del>, <del style="font-weight: bold; text-decoration: none;">Therapie und Nachsorge – Langversion 3</del>.<del style="font-weight: bold; text-decoration: none;">1 – 2018 </del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>*<ins style="font-weight: bold; text-decoration: none;">Brunkhorst FM, Weigand MA, Pletz M, et al. [</ins>S3 <ins style="font-weight: bold; text-decoration: none;">Guideline Sepsis</ins>-<ins style="font-weight: bold; text-decoration: none;">prevention, diagnosis</ins>, <ins style="font-weight: bold; text-decoration: none;">therapy</ins>, <ins style="font-weight: bold; text-decoration: none;">and aftercare : Long version]. Med Klin Intensivmed Notfmed 2020;115(Suppl 2):37–109</ins>.</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The Surviving Sepsis Campaign Bundle: 2018 Update</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*The Surviving Sepsis Campaign Bundle: 2018 Update</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>*Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4185:rev-4186:php=table -->
</table>
imported>Maximilian.schons@uk-koeln.de
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4185&oldid=prev
imported>Maximilian.schons@uk-koeln.de at 14:45, 12 June 2021
2021-06-12T14:45:28Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 14:45, 12 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div><del style="font-weight: bold; text-decoration: none;">==Quellen==</del></div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Langversion 3.1 – 2018 </div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Langversion 3.1 – 2018 </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>The Surviving Sepsis Campaign Bundle: 2018 Update</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>The Surviving Sepsis Campaign Bundle: 2018 Update</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">*</ins>Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>S2k-Leitlinie "Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen – Update 2018</div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td colspan="2" class="diff-side-added"></td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>Interdisziplinäre S3 Leitlinie Epidemiologie, Diagnostik, Therapie Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten Aktualisierung 2017</div></td><td colspan="2" class="diff-side-added"></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4184:rev-4185:php=table -->
</table>
imported>Maximilian.schons@uk-koeln.de
https://wiki.cakele.iodatalabs.dev/index.php?title=DGI:Antibiotikatherapie_bei_Sepsis/Quellen&diff=4184&oldid=prev
imported>Brinkery at 09:32, 4 June 2021
2021-06-04T09:32:30Z
<p></p>
<table style="background-color: #fff; color: #202122;" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="en">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 09:32, 4 June 2021</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1">Line 1:</td>
<td colspan="2" class="diff-lineno">Line 1:</td></tr>
<tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>== Quellen ==</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>==Quellen==</div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Langversion 3.1 – 2018 </div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Langversion 3.1 – 2018 </div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2" class="diff-side-deleted"></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">The Surviving Sepsis Campaign Bundle: 2018 Update</ins></div></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br></td></tr>
<tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>S3-Leitlinie Epidemiologie, Diagnostik und Therapie erwachsener Patienten mit nosokomialer Pneumonie – Update 2017</div></td></tr>
<!-- diff cache key mediawiki:diff:1.41:old-4183:rev-4184:php=table -->
</table>
imported>Brinkery